UK Govt Casts Industry Concerns Aside And Confirms Rise In Statutory Scheme Rebate
Executive Summary
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
You may also be interested in...
Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme
Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.
ABPI Proposes ‘World-First’ Investment Facility As Part Of New Pricing Deal
The Association of the British Pharmaceutical Industry says a new type of investment facility funded by the pharmaceutical industry could form part of a new pricing agreement for branded medicines, and would be a “genuine Brexit dividend.”
ABPI’s 6.88% Rebate Proposal ‘Completely Unaffordable,’ Says UK Health Dept
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.